Industry News

FDA Approves Elamipretide as First Treatment for Barth Syndrome

2025-06-15
FDA Approves Elamipretide as First Treatment for Barth Syndrome

Elamipretide (Forzinity) becomes the first disease-specific treatment approved for Barth syndrome, marking a milestone in rare disease peptide therapeutics.

In 2025, the FDA approved elamipretide (Forzinity) as the first disease-specific treatment for Barth syndrome, a rare genetic disorder. Elamipretide is a peptide-based therapeutic that improves muscle strength in adult and pediatric patients weighing 30 kg or more. The approval highlights the growing impact of peptide-based therapeutics in addressing unmet medical needs for rare diseases. Elamipretide represents a significant milestone as the first targeted treatment for Barth syndrome, which previously had no disease-specific therapies available. This approval is part of the broader 2025 FDA TIDES harvest, which included five TIDES-based therapeutics: one peptide, three oligonucleotides, and one antibody-drug conjugate containing a peptide payload.
Read Full Source Article

Hope to become your Partner

Contact us on Telegram for product inquiries, pricing, and orders.

Contact on Telegram
MINSTAR

Shanghai Minstar Chemical Co., Ltd.
RAW API Supplier | Q2 2026 Catalogue.
Shipping from USA and International warehouses.

All products for research use only, not for human or veterinary use, no sales to individuals.

Quick Links

Official Contact

Building 8, No. 1098, Chuansha Road,
Pudong, Shanghai, China

© 2026 Shanghai Minstar Chemical Co., Ltd. All Rights Reserved. | Prices subject to change without notice.